HRTX Long Call Strategy

HRTX (Heron Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.

HRTX (Heron Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $144.4M, a beta of 1.71 versus the broader market, a 52-week range of 0.74-2.3, average daily share volume of 2.2M, a public-listing history dating back to 1987, approximately 122 full-time employees. These structural characteristics shape how HRTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.71 indicates HRTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on HRTX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current HRTX snapshot

As of May 15, 2026, spot at $0.85, ATM IV 168.40%, IV rank 33.91%, expected move 48.28%. The long call on HRTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on HRTX specifically: HRTX IV at 168.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 48.28% (roughly $0.41 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HRTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on HRTX should anchor to the underlying notional of $0.85 per share and to the trader's directional view on HRTX stock.

HRTX long call setup

The HRTX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HRTX near $0.85, the first option leg uses a $0.85 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HRTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HRTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$0.85N/A

HRTX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

HRTX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on HRTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on HRTX

Long calls on HRTX express a bullish thesis with defined risk; traders use them ahead of HRTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

HRTX thesis for this long call

The market-implied 1-standard-deviation range for HRTX extends from approximately $0.44 on the downside to $1.26 on the upside. A HRTX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current HRTX IV rank near 33.91% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on HRTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, HRTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HRTX-specific events.

HRTX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HRTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HRTX alongside the broader basket even when HRTX-specific fundamentals are unchanged. Long-premium structures like a long call on HRTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current HRTX chain quotes before placing a trade.

Frequently asked questions

What is a long call on HRTX?
A long call on HRTX is the long call strategy applied to HRTX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With HRTX stock trading near $0.85, the strikes shown on this page are snapped to the nearest listed HRTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are HRTX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the HRTX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 168.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a HRTX long call?
The breakeven for the HRTX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HRTX market-implied 1-standard-deviation expected move is approximately 48.28%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on HRTX?
Long calls on HRTX express a bullish thesis with defined risk; traders use them ahead of HRTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current HRTX implied volatility affect this long call?
HRTX ATM IV is at 168.40% with IV rank near 33.91%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related HRTX analysis